Cosmo Pharmaceuticals (OTCMKTS:CMOPF – Get Free Report) was the recipient of a large increase in short interest in September. As of September 15th, there was short interest totaling 15,837 shares, an increase of 112.6% from the August 31st total of 7,450 shares. Based on an average trading volume of 885 shares, the short-interest ratio is currently 17.9 days.
Cosmo Pharmaceuticals Stock Performance
Shares of CMOPF stock opened at C$65.00 on Wednesday. The stock has a 50 day moving average of C$72.02 and a two-hundred day moving average of C$88.69. Cosmo Pharmaceuticals has a 12 month low of C$63.49 and a 12 month high of C$169.90.
About Cosmo Pharmaceuticals
Cosmo Pharmaceuticals N.V. is a specialty pharmaceutical company focused on developing, manufacturing and commercializing products for gastrointestinal and dermatological conditions. Founded in 1997, the company is headquartered in Dublin, Ireland, and has research, development and manufacturing operations in Europe.
Cosmo’s gastrointestinal portfolio includes therapies based on mesalamine and budesonide, including products marketed under the Lialda, Mezavant and Uceris brands through commercial partners in various markets.
Further Reading
- Five stocks we like better than Cosmo Pharmaceuticals
- CarMax Just Gave Investors a Better Reason to Believe in the Turnaround
- CoreWeave Comes With Risks: Analysts Split on What Matters Most
- Bottlenecking the Future: TSMC Prices Out the Competition
- Fervo Energy Hits Geothermal Milestone: Will It Matter For The Stock?
Receive News & Ratings for Cosmo Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cosmo Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
